nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—breast cancer—ovarian cancer	0.547	1	CtDrD
Raloxifene—ESR1—ovarian cancer	0.214	1	CbGaD
Raloxifene—CYP19A1—Paclitaxel—ovarian cancer	0.0354	0.443	CbGbCtD
Raloxifene—CYP2C8—Paclitaxel—ovarian cancer	0.011	0.138	CbGbCtD
Raloxifene—CYP3A4—Topotecan—ovarian cancer	0.00905	0.113	CbGbCtD
Raloxifene—CYP19A1—follicular fluid—ovarian cancer	0.00847	0.152	CbGeAlD
Raloxifene—CYP2B6—Doxorubicin—ovarian cancer	0.00786	0.0985	CbGbCtD
Raloxifene—CYP3A4—Vinorelbine—ovarian cancer	0.00637	0.0799	CbGbCtD
Raloxifene—CYP19A1—corpus luteum—ovarian cancer	0.00488	0.0878	CbGeAlD
Raloxifene—ESR2—ovarian follicle—ovarian cancer	0.00484	0.0871	CbGeAlD
Raloxifene—CYP3A4—Paclitaxel—ovarian cancer	0.00448	0.0561	CbGbCtD
Raloxifene—CYP19A1—ovarian follicle—ovarian cancer	0.00382	0.0686	CbGeAlD
Raloxifene—ESR1—ovarian follicle—ovarian cancer	0.00332	0.0597	CbGeAlD
Raloxifene—CYP3A4—Docetaxel—ovarian cancer	0.00324	0.0406	CbGbCtD
Raloxifene—CYP3A4—Doxorubicin—ovarian cancer	0.00241	0.0302	CbGbCtD
Raloxifene—ESR2—oviduct—ovarian cancer	0.00213	0.0383	CbGeAlD
Raloxifene—EBP—uterine cervix—ovarian cancer	0.00152	0.0274	CbGeAlD
Raloxifene—ESR1—oviduct—ovarian cancer	0.00146	0.0262	CbGeAlD
Raloxifene—EBP—uterus—ovarian cancer	0.00127	0.0228	CbGeAlD
Raloxifene—EBP—female reproductive system—ovarian cancer	0.00114	0.0205	CbGeAlD
Raloxifene—AOX1—myometrium—ovarian cancer	0.000655	0.0118	CbGeAlD
Raloxifene—ESR2—epithelium—ovarian cancer	0.000534	0.00961	CbGeAlD
Raloxifene—ESR2—uterine cervix—ovarian cancer	0.00053	0.00953	CbGeAlD
Raloxifene—SIGMAR1—myometrium—ovarian cancer	0.000528	0.00949	CbGeAlD
Raloxifene—HTR2B—myometrium—ovarian cancer	0.000526	0.00947	CbGeAlD
Raloxifene—AOX1—uterine cervix—ovarian cancer	0.00051	0.00917	CbGeAlD
Raloxifene—AOX1—decidua—ovarian cancer	0.000486	0.00874	CbGeAlD
Raloxifene—ESR2—endometrium—ovarian cancer	0.000479	0.00862	CbGeAlD
Raloxifene—ESR1—myometrium—ovarian cancer	0.000466	0.00839	CbGeAlD
Raloxifene—AOX1—endometrium—ovarian cancer	0.000461	0.0083	CbGeAlD
Raloxifene—ESR1—embryo—ovarian cancer	0.000449	0.00807	CbGeAlD
Raloxifene—ESR2—gonad—ovarian cancer	0.000445	0.008	CbGeAlD
Raloxifene—ESR2—uterus—ovarian cancer	0.000442	0.00794	CbGeAlD
Raloxifene—AOX1—gonad—ovarian cancer	0.000428	0.0077	CbGeAlD
Raloxifene—AOX1—uterus—ovarian cancer	0.000425	0.00765	CbGeAlD
Raloxifene—SIGMAR1—uterine cervix—ovarian cancer	0.000411	0.00738	CbGeAlD
Raloxifene—HTR2B—uterine cervix—ovarian cancer	0.00041	0.00737	CbGeAlD
Raloxifene—ESR2—female reproductive system—ovarian cancer	0.000397	0.00714	CbGeAlD
Raloxifene—SIGMAR1—decidua—ovarian cancer	0.000391	0.00703	CbGeAlD
Raloxifene—HTR2B—decidua—ovarian cancer	0.00039	0.00702	CbGeAlD
Raloxifene—AOX1—female reproductive system—ovarian cancer	0.000382	0.00687	CbGeAlD
Raloxifene—CYP19A1—endometrium—ovarian cancer	0.000378	0.00679	CbGeAlD
Raloxifene—SIGMAR1—endometrium—ovarian cancer	0.000371	0.00668	CbGeAlD
Raloxifene—HTR2B—endometrium—ovarian cancer	0.00037	0.00666	CbGeAlD
Raloxifene—ESR1—epithelium—ovarian cancer	0.000366	0.00658	CbGeAlD
Raloxifene—ESR1—uterine cervix—ovarian cancer	0.000363	0.00653	CbGeAlD
Raloxifene—ESR2—female gonad—ovarian cancer	0.000361	0.0065	CbGeAlD
Raloxifene—ESR2—vagina—ovarian cancer	0.000359	0.00646	CbGeAlD
Raloxifene—CYP19A1—gonad—ovarian cancer	0.00035	0.0063	CbGeAlD
Raloxifene—CYP19A1—uterus—ovarian cancer	0.000348	0.00626	CbGeAlD
Raloxifene—AOX1—female gonad—ovarian cancer	0.000348	0.00625	CbGeAlD
Raloxifene—ESR1—decidua—ovarian cancer	0.000346	0.00622	CbGeAlD
Raloxifene—AOX1—vagina—ovarian cancer	0.000346	0.00622	CbGeAlD
Raloxifene—SIGMAR1—uterus—ovarian cancer	0.000342	0.00615	CbGeAlD
Raloxifene—HTR2B—uterus—ovarian cancer	0.000341	0.00614	CbGeAlD
Raloxifene—ESR1—endometrium—ovarian cancer	0.000328	0.0059	CbGeAlD
Raloxifene—ESR2—testis—ovarian cancer	0.00032	0.00576	CbGeAlD
Raloxifene—CYP19A1—female reproductive system—ovarian cancer	0.000313	0.00563	CbGeAlD
Raloxifene—AOX1—testis—ovarian cancer	0.000308	0.00555	CbGeAlD
Raloxifene—HTR2B—female reproductive system—ovarian cancer	0.000307	0.00552	CbGeAlD
Raloxifene—ESR1—gonad—ovarian cancer	0.000304	0.00548	CbGeAlD
Raloxifene—ESR1—uterus—ovarian cancer	0.000302	0.00544	CbGeAlD
Raloxifene—SIGMAR1—bone marrow—ovarian cancer	0.00029	0.00522	CbGeAlD
Raloxifene—CYP19A1—female gonad—ovarian cancer	0.000285	0.00512	CbGeAlD
Raloxifene—SIGMAR1—female gonad—ovarian cancer	0.00028	0.00503	CbGeAlD
Raloxifene—SIGMAR1—vagina—ovarian cancer	0.000278	0.005	CbGeAlD
Raloxifene—HTR2B—vagina—ovarian cancer	0.000278	0.00499	CbGeAlD
Raloxifene—ESR1—female reproductive system—ovarian cancer	0.000272	0.00489	CbGeAlD
Raloxifene—CYP2C8—endometrium—ovarian cancer	0.00027	0.00486	CbGeAlD
Raloxifene—CYP19A1—testis—ovarian cancer	0.000252	0.00454	CbGeAlD
Raloxifene—SIGMAR1—testis—ovarian cancer	0.000248	0.00446	CbGeAlD
Raloxifene—ESR1—female gonad—ovarian cancer	0.000247	0.00445	CbGeAlD
Raloxifene—ESR1—vagina—ovarian cancer	0.000246	0.00442	CbGeAlD
Raloxifene—ESR2—lymph node—ovarian cancer	0.000232	0.00418	CbGeAlD
Raloxifene—CYP2B6—gonad—ovarian cancer	0.000225	0.00405	CbGeAlD
Raloxifene—CYP2C8—female reproductive system—ovarian cancer	0.000224	0.00403	CbGeAlD
Raloxifene—AOX1—lymph node—ovarian cancer	0.000224	0.00402	CbGeAlD
Raloxifene—ESR1—testis—ovarian cancer	0.000219	0.00395	CbGeAlD
Raloxifene—CYP2C8—vagina—ovarian cancer	0.000203	0.00364	CbGeAlD
Raloxifene—CYP2B6—female reproductive system—ovarian cancer	0.000201	0.00361	CbGeAlD
Raloxifene—CYP19A1—lymph node—ovarian cancer	0.000183	0.00329	CbGeAlD
Raloxifene—CYP2B6—vagina—ovarian cancer	0.000182	0.00327	CbGeAlD
Raloxifene—CYP2C8—testis—ovarian cancer	0.000181	0.00325	CbGeAlD
Raloxifene—SIGMAR1—lymph node—ovarian cancer	0.00018	0.00324	CbGeAlD
Raloxifene—HTR2B—lymph node—ovarian cancer	0.00018	0.00323	CbGeAlD
Raloxifene—CYP2B6—testis—ovarian cancer	0.000162	0.00292	CbGeAlD
Raloxifene—ESR1—lymph node—ovarian cancer	0.000159	0.00286	CbGeAlD
Raloxifene—CYP3A4—female reproductive system—ovarian cancer	0.000152	0.00273	CbGeAlD
Raloxifene—Abdominal pain—Chlorambucil—ovarian cancer	0.000148	0.00213	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000148	0.00213	CcSEcCtD
Raloxifene—Dyspepsia—Topotecan—ovarian cancer	0.000147	0.00211	CcSEcCtD
Raloxifene—Conjunctivitis—Paclitaxel—ovarian cancer	0.000146	0.00211	CcSEcCtD
Raloxifene—Urinary tract infection—Paclitaxel—ovarian cancer	0.000146	0.00211	CcSEcCtD
Raloxifene—Vaginal infection—Epirubicin—ovarian cancer	0.000145	0.00209	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000144	0.00207	CcSEcCtD
Raloxifene—Dyspepsia—Melphalan—ovarian cancer	0.000144	0.00207	CcSEcCtD
Raloxifene—Pain—Topotecan—ovarian cancer	0.000143	0.00205	CcSEcCtD
Raloxifene—Vaginal inflammation—Doxorubicin—ovarian cancer	0.000142	0.00205	CcSEcCtD
Raloxifene—Pulmonary embolism—Doxorubicin—ovarian cancer	0.000142	0.00205	CcSEcCtD
Raloxifene—Infection—Vinorelbine—ovarian cancer	0.000142	0.00204	CcSEcCtD
Raloxifene—Cramps of lower extremities—Epirubicin—ovarian cancer	0.000141	0.00203	CcSEcCtD
Raloxifene—Sinusitis—Paclitaxel—ovarian cancer	0.000141	0.00203	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000141	0.00203	CcSEcCtD
Raloxifene—Nervous system disorder—Vinorelbine—ovarian cancer	0.00014	0.00201	CcSEcCtD
Raloxifene—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00014	0.00201	CcSEcCtD
Raloxifene—Pain—Melphalan—ovarian cancer	0.00014	0.00201	CcSEcCtD
Raloxifene—Bladder pain—Epirubicin—ovarian cancer	0.000139	0.002	CcSEcCtD
Raloxifene—Cystitis noninfective—Doxorubicin—ovarian cancer	0.000139	0.002	CcSEcCtD
Raloxifene—Skin disorder—Vinorelbine—ovarian cancer	0.000139	0.002	CcSEcCtD
Raloxifene—Cystitis—Doxorubicin—ovarian cancer	0.000137	0.00198	CcSEcCtD
Raloxifene—Gastrointestinal pain—Topotecan—ovarian cancer	0.000136	0.00196	CcSEcCtD
Raloxifene—Rhinitis—Paclitaxel—ovarian cancer	0.000135	0.00195	CcSEcCtD
Raloxifene—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000134	0.00193	CcSEcCtD
Raloxifene—Vaginal infection—Doxorubicin—ovarian cancer	0.000134	0.00193	CcSEcCtD
Raloxifene—Pharyngitis—Paclitaxel—ovarian cancer	0.000134	0.00193	CcSEcCtD
Raloxifene—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000133	0.00192	CcSEcCtD
Raloxifene—Oedema peripheral—Paclitaxel—ovarian cancer	0.000133	0.00192	CcSEcCtD
Raloxifene—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000133	0.00191	CcSEcCtD
Raloxifene—Urethral disorder—Paclitaxel—ovarian cancer	0.000132	0.00191	CcSEcCtD
Raloxifene—Body temperature increased—Topotecan—ovarian cancer	0.000132	0.0019	CcSEcCtD
Raloxifene—Abdominal pain—Topotecan—ovarian cancer	0.000132	0.0019	CcSEcCtD
Raloxifene—Cramps of lower extremities—Doxorubicin—ovarian cancer	0.000131	0.00188	CcSEcCtD
Raloxifene—Weight increased—Docetaxel—ovarian cancer	0.00013	0.00187	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00013	0.00187	CcSEcCtD
Raloxifene—Bladder pain—Doxorubicin—ovarian cancer	0.000129	0.00185	CcSEcCtD
Raloxifene—Diabetes mellitus—Epirubicin—ovarian cancer	0.000128	0.00185	CcSEcCtD
Raloxifene—Pneumonia—Docetaxel—ovarian cancer	0.000128	0.00185	CcSEcCtD
Raloxifene—Diarrhoea—Chlorambucil—ovarian cancer	0.000128	0.00185	CcSEcCtD
Raloxifene—Flushing—Paclitaxel—ovarian cancer	0.000125	0.0018	CcSEcCtD
Raloxifene—Cardiac disorder—Paclitaxel—ovarian cancer	0.000125	0.0018	CcSEcCtD
Raloxifene—Conjunctivitis—Docetaxel—ovarian cancer	0.000124	0.00178	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000123	0.00177	CcSEcCtD
Raloxifene—Angiopathy—Paclitaxel—ovarian cancer	0.000123	0.00176	CcSEcCtD
Raloxifene—Pain—Vinorelbine—ovarian cancer	0.000122	0.00176	CcSEcCtD
Raloxifene—Hot flush—Epirubicin—ovarian cancer	0.000119	0.00172	CcSEcCtD
Raloxifene—Vomiting—Chlorambucil—ovarian cancer	0.000119	0.00171	CcSEcCtD
Raloxifene—Diabetes mellitus—Doxorubicin—ovarian cancer	0.000119	0.00171	CcSEcCtD
Raloxifene—Menopausal symptoms—Epirubicin—ovarian cancer	0.000118	0.0017	CcSEcCtD
Raloxifene—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000117	0.00168	CcSEcCtD
Raloxifene—Flatulence—Paclitaxel—ovarian cancer	0.000116	0.00167	CcSEcCtD
Raloxifene—Rhinitis—Docetaxel—ovarian cancer	0.000115	0.00165	CcSEcCtD
Raloxifene—Diarrhoea—Topotecan—ovarian cancer	0.000114	0.00164	CcSEcCtD
Raloxifene—Hypoaesthesia—Docetaxel—ovarian cancer	0.000114	0.00164	CcSEcCtD
Raloxifene—Cerebrovascular accident—Epirubicin—ovarian cancer	0.000114	0.00164	CcSEcCtD
Raloxifene—Pharyngitis—Docetaxel—ovarian cancer	0.000114	0.00164	CcSEcCtD
Raloxifene—Urinary tract disorder—Docetaxel—ovarian cancer	0.000113	0.00163	CcSEcCtD
Raloxifene—Muscle spasms—Paclitaxel—ovarian cancer	0.000113	0.00163	CcSEcCtD
Raloxifene—Abdominal pain—Vinorelbine—ovarian cancer	0.000113	0.00162	CcSEcCtD
Raloxifene—Body temperature increased—Vinorelbine—ovarian cancer	0.000113	0.00162	CcSEcCtD
Raloxifene—Oedema peripheral—Docetaxel—ovarian cancer	0.000113	0.00162	CcSEcCtD
Raloxifene—Connective tissue disorder—Docetaxel—ovarian cancer	0.000112	0.00162	CcSEcCtD
Raloxifene—Urethral disorder—Docetaxel—ovarian cancer	0.000112	0.00162	CcSEcCtD
Raloxifene—Diarrhoea—Melphalan—ovarian cancer	0.000112	0.00161	CcSEcCtD
Raloxifene—Nausea—Chlorambucil—ovarian cancer	0.000111	0.0016	CcSEcCtD
Raloxifene—Hot flush—Doxorubicin—ovarian cancer	0.00011	0.00159	CcSEcCtD
Raloxifene—Dizziness—Topotecan—ovarian cancer	0.00011	0.00159	CcSEcCtD
Raloxifene—Migraine—Epirubicin—ovarian cancer	0.00011	0.00158	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—ovarian cancer	0.000109	0.00158	CcSEcCtD
Raloxifene—Cardiac disorder—Docetaxel—ovarian cancer	0.000106	0.00153	CcSEcCtD
Raloxifene—Flushing—Docetaxel—ovarian cancer	0.000106	0.00153	CcSEcCtD
Raloxifene—Vomiting—Topotecan—ovarian cancer	0.000106	0.00153	CcSEcCtD
Raloxifene—Vertigo—Paclitaxel—ovarian cancer	0.000106	0.00152	CcSEcCtD
Raloxifene—Syncope—Paclitaxel—ovarian cancer	0.000105	0.00152	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000105	0.00152	CcSEcCtD
Raloxifene—Rash—Topotecan—ovarian cancer	0.000105	0.00151	CcSEcCtD
Raloxifene—Dermatitis—Topotecan—ovarian cancer	0.000105	0.00151	CcSEcCtD
Raloxifene—Headache—Topotecan—ovarian cancer	0.000104	0.0015	CcSEcCtD
Raloxifene—Angiopathy—Docetaxel—ovarian cancer	0.000104	0.0015	CcSEcCtD
Raloxifene—Vomiting—Melphalan—ovarian cancer	0.000104	0.00149	CcSEcCtD
Raloxifene—Loss of consciousness—Paclitaxel—ovarian cancer	0.000103	0.00149	CcSEcCtD
Raloxifene—Rash—Melphalan—ovarian cancer	0.000103	0.00148	CcSEcCtD
Raloxifene—Dermatitis—Melphalan—ovarian cancer	0.000103	0.00148	CcSEcCtD
Raloxifene—Cough—Paclitaxel—ovarian cancer	0.000103	0.00148	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—ovarian cancer	0.000102	0.00146	CcSEcCtD
Raloxifene—Breast disorder—Epirubicin—ovarian cancer	0.000101	0.00145	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.0001	0.00145	CcSEcCtD
Raloxifene—Arthralgia—Paclitaxel—ovarian cancer	0.0001	0.00144	CcSEcCtD
Raloxifene—Myalgia—Paclitaxel—ovarian cancer	0.0001	0.00144	CcSEcCtD
Raloxifene—Chest pain—Paclitaxel—ovarian cancer	0.0001	0.00144	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	9.94e-05	0.00143	CcSEcCtD
Raloxifene—Nausea—Topotecan—ovarian cancer	9.9e-05	0.00143	CcSEcCtD
Raloxifene—Diarrhoea—Vinorelbine—ovarian cancer	9.76e-05	0.00141	CcSEcCtD
Raloxifene—Nausea—Melphalan—ovarian cancer	9.7e-05	0.0014	CcSEcCtD
Raloxifene—Influenza—Epirubicin—ovarian cancer	9.64e-05	0.00139	CcSEcCtD
Raloxifene—Muscle spasms—Docetaxel—ovarian cancer	9.58e-05	0.00138	CcSEcCtD
Raloxifene—Infection—Paclitaxel—ovarian cancer	9.53e-05	0.00137	CcSEcCtD
Raloxifene—Shock—Paclitaxel—ovarian cancer	9.44e-05	0.00136	CcSEcCtD
Raloxifene—Dizziness—Vinorelbine—ovarian cancer	9.43e-05	0.00136	CcSEcCtD
Raloxifene—Nervous system disorder—Paclitaxel—ovarian cancer	9.41e-05	0.00135	CcSEcCtD
Raloxifene—Thrombocytopenia—Paclitaxel—ovarian cancer	9.39e-05	0.00135	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—ovarian cancer	9.33e-05	0.00134	CcSEcCtD
Raloxifene—Skin disorder—Paclitaxel—ovarian cancer	9.32e-05	0.00134	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	9.3e-05	0.00134	CcSEcCtD
Raloxifene—Bronchitis—Epirubicin—ovarian cancer	9.27e-05	0.00134	CcSEcCtD
Raloxifene—Hyperhidrosis—Paclitaxel—ovarian cancer	9.27e-05	0.00134	CcSEcCtD
Raloxifene—Vomiting—Vinorelbine—ovarian cancer	9.07e-05	0.00131	CcSEcCtD
Raloxifene—Rash—Vinorelbine—ovarian cancer	8.99e-05	0.0013	CcSEcCtD
Raloxifene—Dermatitis—Vinorelbine—ovarian cancer	8.98e-05	0.00129	CcSEcCtD
Raloxifene—Headache—Vinorelbine—ovarian cancer	8.93e-05	0.00129	CcSEcCtD
Raloxifene—Syncope—Docetaxel—ovarian cancer	8.93e-05	0.00129	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—ovarian cancer	8.92e-05	0.00129	CcSEcCtD
Raloxifene—Weight increased—Epirubicin—ovarian cancer	8.78e-05	0.00126	CcSEcCtD
Raloxifene—Loss of consciousness—Docetaxel—ovarian cancer	8.76e-05	0.00126	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	8.74e-05	0.00126	CcSEcCtD
Raloxifene—Cough—Docetaxel—ovarian cancer	8.69e-05	0.00125	CcSEcCtD
Raloxifene—Insomnia—Paclitaxel—ovarian cancer	8.68e-05	0.00125	CcSEcCtD
Raloxifene—Pneumonia—Epirubicin—ovarian cancer	8.65e-05	0.00125	CcSEcCtD
Raloxifene—Bronchitis—Doxorubicin—ovarian cancer	8.58e-05	0.00124	CcSEcCtD
Raloxifene—Arthralgia—Docetaxel—ovarian cancer	8.48e-05	0.00122	CcSEcCtD
Raloxifene—Chest pain—Docetaxel—ovarian cancer	8.48e-05	0.00122	CcSEcCtD
Raloxifene—Myalgia—Docetaxel—ovarian cancer	8.48e-05	0.00122	CcSEcCtD
Raloxifene—Nausea—Vinorelbine—ovarian cancer	8.47e-05	0.00122	CcSEcCtD
Raloxifene—Dyspepsia—Paclitaxel—ovarian cancer	8.44e-05	0.00122	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	8.42e-05	0.00121	CcSEcCtD
Raloxifene—Urinary tract infection—Epirubicin—ovarian cancer	8.36e-05	0.0012	CcSEcCtD
Raloxifene—Conjunctivitis—Epirubicin—ovarian cancer	8.36e-05	0.0012	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Paclitaxel—ovarian cancer	8.28e-05	0.00119	CcSEcCtD
Raloxifene—Sweating—Epirubicin—ovarian cancer	8.24e-05	0.00119	CcSEcCtD
Raloxifene—Pain—Paclitaxel—ovarian cancer	8.2e-05	0.00118	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—ovarian cancer	8.12e-05	0.00117	CcSEcCtD
Raloxifene—Infection—Docetaxel—ovarian cancer	8.08e-05	0.00116	CcSEcCtD
Raloxifene—Sinusitis—Epirubicin—ovarian cancer	8.07e-05	0.00116	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—ovarian cancer	8e-05	0.00115	CcSEcCtD
Raloxifene—Shock—Docetaxel—ovarian cancer	8e-05	0.00115	CcSEcCtD
Raloxifene—Nervous system disorder—Docetaxel—ovarian cancer	7.97e-05	0.00115	CcSEcCtD
Raloxifene—Thrombocytopenia—Docetaxel—ovarian cancer	7.96e-05	0.00115	CcSEcCtD
Raloxifene—Skin disorder—Docetaxel—ovarian cancer	7.9e-05	0.00114	CcSEcCtD
Raloxifene—Gastrointestinal pain—Paclitaxel—ovarian cancer	7.84e-05	0.00113	CcSEcCtD
Raloxifene—Rhinitis—Epirubicin—ovarian cancer	7.74e-05	0.00111	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—ovarian cancer	7.73e-05	0.00111	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—ovarian cancer	7.73e-05	0.00111	CcSEcCtD
Raloxifene—Hypoaesthesia—Epirubicin—ovarian cancer	7.68e-05	0.00111	CcSEcCtD
Raloxifene—Pharyngitis—Epirubicin—ovarian cancer	7.66e-05	0.0011	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—ovarian cancer	7.63e-05	0.0011	CcSEcCtD
Raloxifene—Urinary tract disorder—Epirubicin—ovarian cancer	7.62e-05	0.0011	CcSEcCtD
Raloxifene—Oedema peripheral—Epirubicin—ovarian cancer	7.6e-05	0.0011	CcSEcCtD
Raloxifene—Connective tissue disorder—Epirubicin—ovarian cancer	7.59e-05	0.00109	CcSEcCtD
Raloxifene—Abdominal pain—Paclitaxel—ovarian cancer	7.58e-05	0.00109	CcSEcCtD
Raloxifene—Body temperature increased—Paclitaxel—ovarian cancer	7.58e-05	0.00109	CcSEcCtD
Raloxifene—Urethral disorder—Epirubicin—ovarian cancer	7.57e-05	0.00109	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—ovarian cancer	7.46e-05	0.00108	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Docetaxel—ovarian cancer	7.41e-05	0.00107	CcSEcCtD
Raloxifene—Insomnia—Docetaxel—ovarian cancer	7.35e-05	0.00106	CcSEcCtD
Raloxifene—Flushing—Epirubicin—ovarian cancer	7.16e-05	0.00103	CcSEcCtD
Raloxifene—Cardiac disorder—Epirubicin—ovarian cancer	7.16e-05	0.00103	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—ovarian cancer	7.16e-05	0.00103	CcSEcCtD
Raloxifene—Dyspepsia—Docetaxel—ovarian cancer	7.16e-05	0.00103	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—ovarian cancer	7.11e-05	0.00102	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—ovarian cancer	7.09e-05	0.00102	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—ovarian cancer	7.05e-05	0.00102	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—ovarian cancer	7.04e-05	0.00101	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Docetaxel—ovarian cancer	7.02e-05	0.00101	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—ovarian cancer	7.02e-05	0.00101	CcSEcCtD
Raloxifene—Angiopathy—Epirubicin—ovarian cancer	7e-05	0.00101	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—ovarian cancer	7e-05	0.00101	CcSEcCtD
Raloxifene—Pain—Docetaxel—ovarian cancer	6.95e-05	0.001	CcSEcCtD
Raloxifene—Gastrointestinal pain—Docetaxel—ovarian cancer	6.65e-05	0.000958	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—ovarian cancer	6.63e-05	0.000955	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—ovarian cancer	6.63e-05	0.000955	CcSEcCtD
Raloxifene—Flatulence—Epirubicin—ovarian cancer	6.62e-05	0.000954	CcSEcCtD
Raloxifene—Diarrhoea—Paclitaxel—ovarian cancer	6.56e-05	0.000945	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—ovarian cancer	6.48e-05	0.000933	CcSEcCtD
Raloxifene—Muscle spasms—Epirubicin—ovarian cancer	6.46e-05	0.00093	CcSEcCtD
Raloxifene—Abdominal pain—Docetaxel—ovarian cancer	6.43e-05	0.000926	CcSEcCtD
Raloxifene—Body temperature increased—Docetaxel—ovarian cancer	6.43e-05	0.000926	CcSEcCtD
Raloxifene—Dizziness—Paclitaxel—ovarian cancer	6.34e-05	0.000914	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—ovarian cancer	6.13e-05	0.000882	CcSEcCtD
Raloxifene—Vomiting—Paclitaxel—ovarian cancer	6.1e-05	0.000878	CcSEcCtD
Raloxifene—Rash—Paclitaxel—ovarian cancer	6.05e-05	0.000871	CcSEcCtD
Raloxifene—Dermatitis—Paclitaxel—ovarian cancer	6.04e-05	0.00087	CcSEcCtD
Raloxifene—Vertigo—Epirubicin—ovarian cancer	6.04e-05	0.000869	CcSEcCtD
Raloxifene—Syncope—Epirubicin—ovarian cancer	6.03e-05	0.000868	CcSEcCtD
Raloxifene—Headache—Paclitaxel—ovarian cancer	6.01e-05	0.000865	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—ovarian cancer	5.98e-05	0.000861	CcSEcCtD
Raloxifene—Loss of consciousness—Epirubicin—ovarian cancer	5.91e-05	0.000851	CcSEcCtD
Raloxifene—Cough—Epirubicin—ovarian cancer	5.86e-05	0.000845	CcSEcCtD
Raloxifene—Arthralgia—Epirubicin—ovarian cancer	5.72e-05	0.000824	CcSEcCtD
Raloxifene—Chest pain—Epirubicin—ovarian cancer	5.72e-05	0.000824	CcSEcCtD
Raloxifene—Myalgia—Epirubicin—ovarian cancer	5.72e-05	0.000824	CcSEcCtD
Raloxifene—Nausea—Paclitaxel—ovarian cancer	5.7e-05	0.000821	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.68e-05	0.000818	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—ovarian cancer	5.59e-05	0.000805	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—ovarian cancer	5.58e-05	0.000803	CcSEcCtD
Raloxifene—Diarrhoea—Docetaxel—ovarian cancer	5.56e-05	0.000801	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—ovarian cancer	5.46e-05	0.000787	CcSEcCtD
Raloxifene—Infection—Epirubicin—ovarian cancer	5.45e-05	0.000785	CcSEcCtD
Raloxifene—Cough—Doxorubicin—ovarian cancer	5.43e-05	0.000781	CcSEcCtD
Raloxifene—Shock—Epirubicin—ovarian cancer	5.4e-05	0.000777	CcSEcCtD
Raloxifene—Nervous system disorder—Epirubicin—ovarian cancer	5.38e-05	0.000775	CcSEcCtD
Raloxifene—Dizziness—Docetaxel—ovarian cancer	5.38e-05	0.000774	CcSEcCtD
Raloxifene—Thrombocytopenia—Epirubicin—ovarian cancer	5.37e-05	0.000773	CcSEcCtD
Raloxifene—Skin disorder—Epirubicin—ovarian cancer	5.33e-05	0.000767	CcSEcCtD
Raloxifene—Hyperhidrosis—Epirubicin—ovarian cancer	5.3e-05	0.000764	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—ovarian cancer	5.29e-05	0.000762	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—ovarian cancer	5.29e-05	0.000762	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—ovarian cancer	5.29e-05	0.000762	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.26e-05	0.000757	CcSEcCtD
Raloxifene—Vomiting—Docetaxel—ovarian cancer	5.17e-05	0.000745	CcSEcCtD
Raloxifene—Rash—Docetaxel—ovarian cancer	5.13e-05	0.000738	CcSEcCtD
Raloxifene—Dermatitis—Docetaxel—ovarian cancer	5.12e-05	0.000738	CcSEcCtD
Raloxifene—Headache—Docetaxel—ovarian cancer	5.09e-05	0.000734	CcSEcCtD
Raloxifene—Infection—Doxorubicin—ovarian cancer	5.04e-05	0.000726	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5e-05	0.00072	CcSEcCtD
Raloxifene—Shock—Doxorubicin—ovarian cancer	4.99e-05	0.000719	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—ovarian cancer	4.98e-05	0.000717	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—ovarian cancer	4.97e-05	0.000716	CcSEcCtD
Raloxifene—Insomnia—Epirubicin—ovarian cancer	4.96e-05	0.000714	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—ovarian cancer	4.93e-05	0.00071	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—ovarian cancer	4.91e-05	0.000706	CcSEcCtD
Raloxifene—Nausea—Docetaxel—ovarian cancer	4.83e-05	0.000696	CcSEcCtD
Raloxifene—Dyspepsia—Epirubicin—ovarian cancer	4.83e-05	0.000695	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.73e-05	0.000682	CcSEcCtD
Raloxifene—Pain—Epirubicin—ovarian cancer	4.69e-05	0.000675	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.62e-05	0.000666	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—ovarian cancer	4.59e-05	0.000661	CcSEcCtD
Raloxifene—Gastrointestinal pain—Epirubicin—ovarian cancer	4.48e-05	0.000646	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—ovarian cancer	4.47e-05	0.000643	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.38e-05	0.000631	CcSEcCtD
Raloxifene—Pain—Doxorubicin—ovarian cancer	4.34e-05	0.000625	CcSEcCtD
Raloxifene—Body temperature increased—Epirubicin—ovarian cancer	4.34e-05	0.000624	CcSEcCtD
Raloxifene—Abdominal pain—Epirubicin—ovarian cancer	4.34e-05	0.000624	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.15e-05	0.000598	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—ovarian cancer	4.01e-05	0.000578	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—ovarian cancer	4.01e-05	0.000578	CcSEcCtD
Raloxifene—Diarrhoea—Epirubicin—ovarian cancer	3.75e-05	0.00054	CcSEcCtD
Raloxifene—Dizziness—Epirubicin—ovarian cancer	3.63e-05	0.000522	CcSEcCtD
Raloxifene—Vomiting—Epirubicin—ovarian cancer	3.49e-05	0.000502	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—ovarian cancer	3.47e-05	0.0005	CcSEcCtD
Raloxifene—Rash—Epirubicin—ovarian cancer	3.46e-05	0.000498	CcSEcCtD
Raloxifene—Dermatitis—Epirubicin—ovarian cancer	3.45e-05	0.000498	CcSEcCtD
Raloxifene—Headache—Epirubicin—ovarian cancer	3.44e-05	0.000495	CcSEcCtD
Raloxifene—Dizziness—Doxorubicin—ovarian cancer	3.36e-05	0.000483	CcSEcCtD
Raloxifene—Nausea—Epirubicin—ovarian cancer	3.26e-05	0.000469	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—ovarian cancer	3.23e-05	0.000465	CcSEcCtD
Raloxifene—Rash—Doxorubicin—ovarian cancer	3.2e-05	0.000461	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—ovarian cancer	3.2e-05	0.00046	CcSEcCtD
Raloxifene—Headache—Doxorubicin—ovarian cancer	3.18e-05	0.000458	CcSEcCtD
Raloxifene—Nausea—Doxorubicin—ovarian cancer	3.01e-05	0.000434	CcSEcCtD
Raloxifene—CYP19A1—Metabolism—SLC5A5—ovarian cancer	9.89e-06	0.000288	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PARP1—ovarian cancer	9.86e-06	0.000287	CbGpPWpGaD
Raloxifene—AOX1—Disease—ERBB2—ovarian cancer	9.75e-06	0.000284	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PGR—ovarian cancer	9.68e-06	0.000282	CbGpPWpGaD
Raloxifene—AOX1—Disease—MTOR—ovarian cancer	9.62e-06	0.00028	CbGpPWpGaD
Raloxifene—AOX1—Disease—PIK3CB—ovarian cancer	9.62e-06	0.00028	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—SLC2A1—ovarian cancer	9.55e-06	0.000278	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NME2—ovarian cancer	9.53e-06	0.000277	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL6ST—ovarian cancer	9.43e-06	0.000274	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.35e-06	0.000272	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PPP2R1A—ovarian cancer	9.35e-06	0.000272	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CD—ovarian cancer	9.24e-06	0.000269	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—YAP1—ovarian cancer	9.23e-06	0.000269	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CYP1B1—ovarian cancer	9.16e-06	0.000266	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CG—ovarian cancer	9.11e-06	0.000265	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CG—ovarian cancer	9.06e-06	0.000264	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—XIAP—ovarian cancer	9.04e-06	0.000263	CbGpPWpGaD
Raloxifene—AOX1—Disease—CDKN1B—ovarian cancer	9.03e-06	0.000263	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PARP1—ovarian cancer	9e-06	0.000262	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PIK3CA—ovarian cancer	8.86e-06	0.000258	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SMARCA4—ovarian cancer	8.81e-06	0.000256	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CD—ovarian cancer	8.77e-06	0.000255	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL6ST—ovarian cancer	8.61e-06	0.00025	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EREG—ovarian cancer	8.6e-06	0.00025	CbGpPWpGaD
Raloxifene—AOX1—Disease—CTNNB1—ovarian cancer	8.53e-06	0.000248	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTEN—ovarian cancer	8.31e-06	0.000242	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CG—ovarian cancer	8.27e-06	0.000241	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PPP2R1A—ovarian cancer	8.12e-06	0.000236	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.08e-06	0.000235	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PGR—ovarian cancer	8.06e-06	0.000235	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CB—ovarian cancer	8.05e-06	0.000234	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CD—ovarian cancer	8e-06	0.000233	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PPP2R1A—ovarian cancer	7.99e-06	0.000233	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CD—ovarian cancer	7.96e-06	0.000232	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—YAP1—ovarian cancer	7.92e-06	0.00023	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CB—ovarian cancer	7.64e-06	0.000222	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ABCB1—ovarian cancer	7.54e-06	0.000219	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PARP1—ovarian cancer	7.49e-06	0.000218	CbGpPWpGaD
Raloxifene—AOX1—Disease—STAT3—ovarian cancer	7.43e-06	0.000216	CbGpPWpGaD
Raloxifene—AOX1—Disease—NRAS—ovarian cancer	7.41e-06	0.000216	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—TYMS—ovarian cancer	7.41e-06	0.000216	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CXCL8—ovarian cancer	7.35e-06	0.000214	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PPP2R1A—ovarian cancer	7.3e-06	0.000212	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	7.29e-06	0.000212	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CD—ovarian cancer	7.27e-06	0.000212	CbGpPWpGaD
Raloxifene—EBP—Metabolism—AKT1—ovarian cancer	7.24e-06	0.000211	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—MYC—ovarian cancer	7.15e-06	0.000208	CbGpPWpGaD
Raloxifene—AOX1—Disease—MAPK3—ovarian cancer	7.1e-06	0.000207	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MAPK3—ovarian cancer	7.02e-06	0.000204	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—IL2—ovarian cancer	7.02e-06	0.000204	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CB—ovarian cancer	6.98e-06	0.000203	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTEN—ovarian cancer	6.96e-06	0.000203	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CB—ovarian cancer	6.94e-06	0.000202	CbGpPWpGaD
Raloxifene—AOX1—Disease—MYC—ovarian cancer	6.91e-06	0.000201	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MYC—ovarian cancer	6.83e-06	0.000199	CbGpPWpGaD
Raloxifene—AOX1—Disease—MAPK1—ovarian cancer	6.76e-06	0.000197	CbGpPWpGaD
Raloxifene—AOX1—Disease—EGFR—ovarian cancer	6.75e-06	0.000197	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—YAP1—ovarian cancer	6.71e-06	0.000195	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CXCL8—ovarian cancer	6.7e-06	0.000195	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CXCL8—ovarian cancer	6.67e-06	0.000194	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.64e-06	0.000193	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—FASN—ovarian cancer	6.46e-06	0.000188	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—IL2—ovarian cancer	6.41e-06	0.000186	CbGpPWpGaD
Raloxifene—AOX1—Disease—KRAS—ovarian cancer	6.38e-06	0.000186	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL2—ovarian cancer	6.37e-06	0.000186	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TERT—ovarian cancer	6.35e-06	0.000185	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SLC5A5—ovarian cancer	6.35e-06	0.000185	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CB—ovarian cancer	6.34e-06	0.000184	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYTB—ovarian cancer	6.14e-06	0.000179	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SLC2A1—ovarian cancer	6.13e-06	0.000178	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CXCL8—ovarian cancer	6.09e-06	0.000177	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PPP2R1A—ovarian cancer	6.08e-06	0.000177	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CAV1—ovarian cancer	5.97e-06	0.000174	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP1B1—ovarian cancer	5.88e-06	0.000171	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CAV1—ovarian cancer	5.87e-06	0.000171	CbGpPWpGaD
Raloxifene—AOX1—Disease—PIK3CA—ovarian cancer	5.86e-06	0.000171	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.83e-06	0.00017	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL2—ovarian cancer	5.82e-06	0.000169	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TERT—ovarian cancer	5.8e-06	0.000169	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.7e-06	0.000166	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ESR1—ovarian cancer	5.66e-06	0.000165	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6ST—ovarian cancer	5.57e-06	0.000162	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—FASN—ovarian cancer	5.47e-06	0.000159	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CG—ovarian cancer	5.44e-06	0.000158	CbGpPWpGaD
Raloxifene—AOX1—Disease—HRAS—ovarian cancer	5.42e-06	0.000158	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC5A5—ovarian cancer	5.38e-06	0.000156	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—BRIP1—ovarian cancer	5.37e-06	0.000156	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPP1CC—ovarian cancer	5.37e-06	0.000156	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CAV1—ovarian cancer	5.36e-06	0.000156	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APC—ovarian cancer	5.35e-06	0.000156	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CG—ovarian cancer	5.35e-06	0.000156	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—NRAS—ovarian cancer	5.35e-06	0.000156	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	5.22e-06	0.000152	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC2A1—ovarian cancer	5.19e-06	0.000151	CbGpPWpGaD
Raloxifene—AOX1—Disease—IL6—ovarian cancer	5.19e-06	0.000151	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ESR1—ovarian cancer	5.17e-06	0.00015	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—MAPK3—ovarian cancer	5.12e-06	0.000149	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.08e-06	0.000148	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6ST—ovarian cancer	5.08e-06	0.000148	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP1B1—ovarian cancer	4.98e-06	0.000145	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CA—ovarian cancer	4.91e-06	0.000143	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APC—ovarian cancer	4.88e-06	0.000142	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CG—ovarian cancer	4.88e-06	0.000142	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—NRAS—ovarian cancer	4.88e-06	0.000142	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—MAPK1—ovarian cancer	4.88e-06	0.000142	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—ovarian cancer	4.88e-06	0.000142	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ABCB1—ovarian cancer	4.84e-06	0.000141	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TERT—ovarian cancer	4.83e-06	0.000141	CbGpPWpGaD
Raloxifene—AOX1—Disease—AKT1—ovarian cancer	4.79e-06	0.000139	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CD—ovarian cancer	4.78e-06	0.000139	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TYMS—ovarian cancer	4.76e-06	0.000138	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—AKT1—ovarian cancer	4.74e-06	0.000138	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CD—ovarian cancer	4.7e-06	0.000137	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—MAPK3—ovarian cancer	4.68e-06	0.000136	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CA—ovarian cancer	4.66e-06	0.000136	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—ovarian cancer	4.61e-06	0.000134	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CAV1—ovarian cancer	4.47e-06	0.00013	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—MAPK1—ovarian cancer	4.45e-06	0.00013	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—ovarian cancer	4.45e-06	0.00013	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	4.42e-06	0.000128	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.39e-06	0.000128	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CD—ovarian cancer	4.29e-06	0.000125	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CA—ovarian cancer	4.25e-06	0.000124	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6ST—ovarian cancer	4.23e-06	0.000123	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CA—ovarian cancer	4.23e-06	0.000123	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—ovarian cancer	4.2e-06	0.000122	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CB—ovarian cancer	4.16e-06	0.000121	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ERBB2—ovarian cancer	4.15e-06	0.000121	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CB—ovarian cancer	4.1e-06	0.000119	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MTOR—ovarian cancer	4.1e-06	0.000119	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ABCB1—ovarian cancer	4.1e-06	0.000119	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CG—ovarian cancer	4.07e-06	0.000118	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APC—ovarian cancer	4.07e-06	0.000118	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TYMS—ovarian cancer	4.03e-06	0.000117	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AKT1—ovarian cancer	4.01e-06	0.000117	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL8—ovarian cancer	3.94e-06	0.000115	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HRAS—ovarian cancer	3.91e-06	0.000114	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CA—ovarian cancer	3.86e-06	0.000112	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1B—ovarian cancer	3.85e-06	0.000112	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CAV1—ovarian cancer	3.83e-06	0.000112	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKT1—ovarian cancer	3.81e-06	0.000111	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ERBB2—ovarian cancer	3.79e-06	0.00011	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CASP3—ovarian cancer	3.77e-06	0.00011	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL2—ovarian cancer	3.77e-06	0.00011	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL6—ovarian cancer	3.75e-06	0.000109	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MTOR—ovarian cancer	3.74e-06	0.000109	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CB—ovarian cancer	3.74e-06	0.000109	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—ovarian cancer	3.67e-06	0.000107	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CTNNB1—ovarian cancer	3.64e-06	0.000106	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—YAP1—ovarian cancer	3.6e-06	0.000105	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—ovarian cancer	3.6e-06	0.000105	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL8—ovarian cancer	3.6e-06	0.000105	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CD—ovarian cancer	3.58e-06	0.000104	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HRAS—ovarian cancer	3.57e-06	0.000104	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MMP9—ovarian cancer	3.56e-06	0.000104	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—ovarian cancer	3.54e-06	0.000103	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MAPK3—ovarian cancer	3.54e-06	0.000103	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1B—ovarian cancer	3.51e-06	0.000102	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CG—ovarian cancer	3.49e-06	0.000102	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKT1—ovarian cancer	3.47e-06	0.000101	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKT1—ovarian cancer	3.46e-06	0.000101	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MYC—ovarian cancer	3.44e-06	0.0001	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CASP3—ovarian cancer	3.44e-06	0.0001	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL2—ovarian cancer	3.44e-06	0.0001	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL6—ovarian cancer	3.42e-06	9.95e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—ovarian cancer	3.35e-06	9.75e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CTNNB1—ovarian cancer	3.32e-06	9.66e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP9—ovarian cancer	3.25e-06	9.47e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CAV1—ovarian cancer	3.24e-06	9.44e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—ovarian cancer	3.23e-06	9.41e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—ovarian cancer	3.2e-06	9.31e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STAT3—ovarian cancer	3.17e-06	9.22e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NRAS—ovarian cancer	3.16e-06	9.2e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB2—ovarian cancer	3.16e-06	9.19e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKT1—ovarian cancer	3.16e-06	9.18e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MTOR—ovarian cancer	3.12e-06	9.07e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CB—ovarian cancer	3.12e-06	9.07e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.1e-06	9.02e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CD—ovarian cancer	3.07e-06	8.93e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK3—ovarian cancer	3.03e-06	8.81e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL8—ovarian cancer	3e-06	8.72e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CG—ovarian cancer	2.96e-06	8.6e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MYC—ovarian cancer	2.94e-06	8.57e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—FASN—ovarian cancer	2.93e-06	8.54e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1B—ovarian cancer	2.93e-06	8.51e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—ovarian cancer	2.92e-06	8.5e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STAT3—ovarian cancer	2.89e-06	8.42e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.89e-06	8.4e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NRAS—ovarian cancer	2.89e-06	8.4e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK1—ovarian cancer	2.88e-06	8.38e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—ovarian cancer	2.88e-06	8.38e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CASP3—ovarian cancer	2.87e-06	8.35e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL2—ovarian cancer	2.86e-06	8.33e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—ovarian cancer	2.79e-06	8.12e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.79e-06	8.11e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CTNNB1—ovarian cancer	2.76e-06	8.04e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK3—ovarian cancer	2.76e-06	8.04e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—ovarian cancer	2.72e-06	7.92e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP9—ovarian cancer	2.71e-06	7.89e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—ovarian cancer	2.69e-06	7.84e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MYC—ovarian cancer	2.69e-06	7.82e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CB—ovarian cancer	2.67e-06	7.78e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.67e-06	7.78e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK1—ovarian cancer	2.63e-06	7.65e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—ovarian cancer	2.63e-06	7.65e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CD—ovarian cancer	2.6e-06	7.56e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CA—ovarian cancer	2.54e-06	7.39e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CA—ovarian cancer	2.5e-06	7.27e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—ovarian cancer	2.48e-06	7.23e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—ovarian cancer	2.43e-06	7.08e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—ovarian cancer	2.42e-06	7.04e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STAT3—ovarian cancer	2.41e-06	7.01e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NRAS—ovarian cancer	2.4e-06	6.99e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—AKT1—ovarian cancer	2.39e-06	6.95e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.37e-06	6.9e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HRAS—ovarian cancer	2.31e-06	6.73e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—ovarian cancer	2.31e-06	6.73e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK3—ovarian cancer	2.3e-06	6.7e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	2.28e-06	6.64e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CB—ovarian cancer	2.26e-06	6.59e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MYC—ovarian cancer	2.24e-06	6.52e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6—ovarian cancer	2.21e-06	6.44e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—ovarian cancer	2.21e-06	6.42e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.2e-06	6.4e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK1—ovarian cancer	2.19e-06	6.37e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—ovarian cancer	2.19e-06	6.37e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TYMS—ovarian cancer	2.16e-06	6.29e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HRAS—ovarian cancer	2.11e-06	6.14e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKT1—ovarian cancer	2.07e-06	6.04e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—ovarian cancer	2.07e-06	6.02e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKT1—ovarian cancer	2.04e-06	5.94e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6—ovarian cancer	2.02e-06	5.88e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—ovarian cancer	1.96e-06	5.69e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CA—ovarian cancer	1.9e-06	5.53e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKT1—ovarian cancer	1.86e-06	5.42e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—ovarian cancer	1.84e-06	5.35e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HRAS—ovarian cancer	1.76e-06	5.12e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CAV1—ovarian cancer	1.74e-06	5.07e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6—ovarian cancer	1.68e-06	4.9e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CA—ovarian cancer	1.63e-06	4.75e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.59e-06	4.62e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKT1—ovarian cancer	1.55e-06	4.52e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.39e-06	4.06e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.38e-06	4.02e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKT1—ovarian cancer	1.33e-06	3.88e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.22e-06	3.54e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKT1—ovarian cancer	1.13e-06	3.28e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—ovarian cancer	1.05e-06	3.06e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CA—ovarian cancer	7.41e-07	2.16e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKT1—ovarian cancer	6.05e-07	1.76e-05	CbGpPWpGaD
